Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02423902 · ClinicalTrials.gov registry record · Phase 1
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
A Phase 1 study, sponsored by Alaunos Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02423902 is a Phase 1 study that was terminated before completion, run by Alaunos Therapeutics. The registered enrollment target is 9 participants.
The verdict
NCT02423902, a Phase 1 study, was terminated before completion, sponsored by Alaunos Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a single-arm, phase Ib/II study to examine the safety, tolerability and preliminary efficacy of one cycle of Ad-RTS-hIL-12 immunotherapy in women with advanced breast cancer and pre-study SD or PR after completion of a minimum 12 week course of standard first- or second-line chemotherapy. The patient population will include patients with locally advanced or metastatic breast cancer of all subtypes.
Interventions
- BIOLOGICAL Ad-RTS-hIL-12
- DRUG Veledimex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-07-18 |
| Est. Completion | 2016-07-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02423902
The ClinicalTrials.gov registry entry for NCT02423902 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alaunos Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ad-RTS-hIL-12 is the first listed.
NCT02423902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02423902 about?
NCT02423902 is a clinical study titled "A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer". This is a single-arm, phase Ib/II study to examine the safety, tolerability and preliminary efficacy of one cycle of Ad-RTS-hIL-12 immunotherapy in women with advanced breast cancer and pre-study SD or PR after completion of a minimum 12 week course of standard first- or second-line chemotherapy. Th...
What is the current status of trial NCT02423902?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-07-18. Estimated completion is 2016-07-19.
What interventions are being tested in trial NCT02423902?
The interventions under investigation include: Ad-RTS-hIL-12 (BIOLOGICAL), Veledimex (DRUG).
Who is sponsoring clinical trial NCT02423902?
This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.